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Urocortin3 (UCN3) regulates metabolic functions and is involved in cellular stress
response. Although UCN3 is expressed in human adipose tissue, the association of
UCN3 with obesity and diabetes remains unclear. This study investigated the effects of
Type 2 diabetes (T2D) and increased body weight on the circulatory and subcutaneous
adipose tissue (SAT) levels of UCN3 and assessed UCN3 modulation by a regular
physical exercise. Normal-weight (n = 37) and overweight adults with and without
T2D (n = 98 and n = 107, respectively) were enrolled in the study. A subset of the
overweight subjects (n = 39 for each group) underwent a supervised 3-month exercise
program combining both moderate intensity aerobic exercise and resistance training with
treadmill. UCN3 levels in SAT were measured by immunofluorescence and RT-PCR.
Circulatory UCN3 in plasma was assessed by ELISA and was correlated with various
clinical and metabolic markers. Our data revealed that plasma UCN3 levels decreased
in overweight subjects without T2D compared with normal-weight controls [median;
11.99 (0.78–86.07) and 6.27 (0.64–77.04), respectively; p < 0.001], whereas plasma
UCN3 levels increased with concomitant T2D [median; 9.03 (0.77–104.92) p < 0.001].
UCN3 plasma levels were independently associated with glycemic index; fasting plasma
glucose and hemoglobin A1c (r = 0.16 and r = 0.20, p < 0.05, respectively) and were
significantly different between both overweight, with and without T2D, and normal-weight
individuals (OR = 2.11 [1.84–4.11, 95% CI] and OR = 2.12 [1.59–3.10, 95% CI],
p < 0.01, respectively). Conversely, the UCN3 patterns observed in SAT were opposite
to those in circulation; UCN3 levels were significantly increased with body weight and
decreased with T2D. After a 3-month supervised exercise protocol, UCN3 expression
showed a significant reduction in SAT of both overweight groups (2.3 and 1.6-fold
change; p < 0.01, respectively). In conclusion, UCN levels are differentially dysregulated
in obesity in a tissue-dependent manner and can be mitigated by regular moderate
physical exercise.
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INTRODUCTION
Chronic metabolic stress and low-grade inflammation are key
factors in obesity, insulin resistance and Type 2 diabetes
(T2D) and involve the impairment of mechanisms in both
central and peripheral tissues (1). Corticotropin-releasing factor
(CRF) neuropeptides are involved in such mechanisms (2). In
mammals, the CRF family comprises four structurally related
ligands, CRF, and urocortin (UCN) 1–3 (3, 4), which have
been implicated in stress adaptation responses and energy
balance regulation (2) and exhibit proinflammatory and/or anti-
inflammatory effects depending on the context and disease (5,
6). CRF peptides were initially discovered in the brain but
are also expressed in peripheral metabolic tissues, including
skeletal muscle and the pancreas (7, 8). Although the CRF
system is not yet fully understood, its modulation has been
proposed as treatment for human metabolic disorders (5). The
genetic manipulations of the CRF family in mouse models has
demonstrated distinct metabolic phenotypes, thus suggesting
different but crucial endogenous roles for each of these peptides
and their receptors in metabolic pathways (9).
UCN3 is the least studied member of the CRF family, but
it is known to bind and signal selectively via CRF receptor 2
(CRFR2) (10, 11). UCN3 is highly expressed in the pancreas,
where it is exclusively expressed by β-cells in mouse islets but
is expressed by both β-and α-cells in humans (12, 13). The
abundance of UCN3 is decreased in β-cells in patients with T2D
or in macaques fed with a high-fat diet (12). UCN3 enhances
glucose-induced insulin secretion via endogenous and paracrine
action in the pancreas, ensuring the coordinated release of insulin
and glucagon (12, 14). The decreased expression of UCN3 in
pancreatic β-cells in patients with diabetes revealed the loss of
this feedback mechanism (12). UCN3 also contributes to energy
homeostasis in key peripheral metabolic tissues (15, 16). In line
with this, Global overexpression of UCN3 in mice resulted in
resistance to the adverse metabolic effects of a high-fat diet while
local UCN3 expression in muscle enhanced glucose disposal and
signaling in this tissue (17). In a cross-species association study,
UCN3 was proposed to be linked to obesity due to its location
on human chromosome 10p15.1 where quantitative trait loci for
obesity have been reported (18).
Increased expression of UCN3 is thought to protect
from high-fat diet-induced hyperglycemia and can increase
energy expenditure (9).Therefore, UCN3 represents a potential
therapeutic target for metabolic diseases management. However,
the distribution of CRFR2 and UCN3 in adipose tissue and the
mechanisms underlying their role in obesity and adipose tissue-
related insulin resistance remain unclear. Despite the pivotal
role of UCN3 in energy homeostasis and insulin secretion, the
circulating and adipose tissue levels of UCN3 in obese people
with or without T2D have not been previously reported.
Abbreviations: DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; HDL,
high-density lipoprotein; HR, heart rate; hsCRP, high-sensitivity CRP; LDL, low-
density lipoprotein; PBF, percent body fat; SAT, subcutaneous adipose tissue;
PBMC, peripheral blood mononuclear cell; SBP, systolic blood pressure; TGL,
triglyceride; UCN, Urocortin; VO2,max, maximum oxygen consumption; WC,
waist circumference.
Regular physical exercise has become a key component in
the non-pharmacologic treatment and lifestyle management of
people with obesity and diabetes (19, 20). Several studies reported
a reduction in the incidence of diabetes among physically
active individuals (21). Beneficial effects of exercise go beyond
body weight loss and include enhanced insulin sensitivity and
mitochondrial function and lowered risk of cardiovascular
diseases (22). Previous studies including ours have associated
the protective effects of exercise with improved inflammation
andmetabolic stress responses (20, 23–25). Furthermore, exercise
affects various central nervous systems related to energy
homeostasis and food intake via the activation of the CRF/CRH
pathway and the modulation of leptin signaling (14, 26).
Considering the available data on UCN3 and its family
members, we hypothesized that UCN3 expression is increased
in adipose tissue and blood in obese people and decreased with
diabetes and thus affecting the cross talk between the brain and
peripheral organs. Hence, this study investigated the following:
(1) UCN3 levels in the blood and subcutaneous adipose tissue
(SAT) from normal-weight and overweight individuals with and
without T2D; (2) the association between UCN3 levels and
physical, clinical, and biochemical markers; and (3) the effect of
a 3-month physical exercise program on UCN3 levels in obesity
and T2D.
METHODS
Study Population
The study included 3 groups of adults: normal-weight without
T2D (n = 37), overweight without T2D (n = 107), and
overweight with T2D (n = 98). Written informed consent was
obtained from all participants prior to starting this study, which
was approved by the Review Board of Dasman Diabetes Institute
and was conducted in line with the principles of the Declaration
of Helsinki. People who performed regular physical exercise
within the last 6 months prior enrollment to the study or
those with history of major illness or medications not related to
diabetes were excluded.
Exercise Protocol and Anthropometric
Measurements
All eligible subjects (n = 39 for each overweight group)
were enrolled in a supervised exercise program at the
Medical Fitness Center (MFC) of Dasman Diabetes Institute.
Prior to exercise prescription each subject underwent the
Cardiopulmonary exercise test “CPET” (COSMED, Quark, Italy)
using electromagnetically braked cycle ergometer to measure
the maximum heart rate (max HR) and maximum oxygen
consumption (VO2max). Physical fitness was assessed thereafter
to determine the muscle strength, endurance, and flexibility by
performing grip strength (dynamometer), push-ups upper body
strength, sit ups and forward bending test (upper and lower
body flexibility). The exercise program involved a combination
of both resistance training with treadmill or cycling andmoderate
intensity aerobic exercise. Each exercise session included 10min
warming up and cooling down steps at 50–60% of max HR with
40min of the mentioned program at 65–80% of max HR. Under
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the supervision of qualified fitness professionals at MFC, subjects
exercised 3 times per week for a period of 3 months. They were
monitored to maintain the recommended heart rates during the
training. Exercise effectiveness was assessed at the end of the
3-month exercise program using similar fitness tests performed
at baseline.
Blood and Tissue Sampling and Blood
Analysis
SAT biopsies and venous peripheral blood were obtained at
baseline and after the 3-month exercise and processed as
previously reported (27). Briefly, Plasma and serum were
prepared using vacutainer tubes and then aliquoted and stored
at −80◦C. SAT biopsies (200–500mg) were obtained from the
periumbilical area by surgical biopsy after a local anesthesia.
Once removed, the biopsy was rinsed in cold PBS, divided into
four pieces, and stored appropriately until assayed. Blood clinical
markers, plasma inflammatory and metabolic markers were
measured as previously reported (27). Lipid and glucose levels
were measured with a Siemens Dimension Chemistry Analyzer
(Diamond Diagnostics, Holliston, MA, USA). Hemoglobin A1c
(HbA1c) levels were determined with the VariantTM device (Bio-
Rad, Hercules, CA, USA). Plasma levels of UCN3 (#LS-F12902,
Lifespan Biosciences, USA), hsCRP (Biovendor, Asheville, NC,
USA) and insulin (Mercodia AB, Uppsala, Sweden) were
assayed using ELISA kits, in accordance with the manufacturers’
instructions. Plasma samples were diluted 1:10 prior to UCN3
measurement to fit within the detection range.
Immunofluorescence Confocal Microscopy
Formalin-fixed, paraffin-embedded SAT sections (8µm) from
normal-weight and overweight with and without T2D subjects (n
= 6 for each group) were deparaffinized and rehydrated followed
by the antigen retrieval using DAKO solution at pH 6 (Dako,
Glostrup, Denmark) in a pressurized cooker. The endogenous
peroxidase was quenched using 3% H2O2 for 1 h at room
temperature (RT). Sections were blocked with 5% fat-free milk
for 1 h at RT, followed by 1% BSA for 1 h. Then the tissue sections
were incubated at 4◦C for overnight with primary antibodies
(dilution 1:100). Primary antibodies used were anti-UCN3
antibody (ab79121, Abcam, UK) and anti-adiponectin (#5901,
BioVision, USA). Antibody performance was assessed using
negative controls (slides incubated without primary antibody or
with unspecific IgG). Staining with Alexa Fluor 488-conjugated
rabbit secondary antibody (A-11008, Invitrogen, USA) was used
at 1:1,000 dilution and incubated at RT for 1 h. Human pancreas
biopsies were used as positive controls for UCN3 expression.
DAPI was used at 0.05% for nuclear staining. The sections
were analyzed using a Zeiss LSM 710 confocal laser-scanning
microscope (Zeiss, Germany), and 12 fluorescent images of the
representative areas of the SAT were photographed at 40×
objective for each subject. The staining intensities were quantified
using the ZEN software (Zeiss, Germany).
Cell Culture and Treatments
Mouse preadipocyte (3T3-L1) andmacrophage cells (RAW264.7)
were obtained from ATCC (VA, USA), cultured and
differentiated in their growth media as previously reported
(28). For Indirect co-culture of 3T3L1 and RAW264.7 cells,
media from RAW264.7cells were collected and sterile filtered
(0.2µm). The 3T3L1 cells were induced for differentiation using
macrophage-conditioned media (MaCM) supplemented with
differentiation cocktail [1% PS, 10% BCS, 0.5mM 3-isobutyl1-
methylxanthine (IBMX), 1µM dexamethasone, and 1µg/mL
insulin] for 2 days. The medium was then changed to MaCM
with 10% BCS and insulin (1µg/mL) and replaced every 2 days
up to day 8.
Oil Red O Staining
After treatment with RAW264.7 cells conditioned media, 3T3-L1
cells were washed twice with PBS, fixed with 10% formalin for
1 h at RT, washed twice again with PBS, and incubated with 60%
isopropanol for 5min. Finally, cells were incubated with 0.3% Oil
Red O solution for 20min. Coverslips were washed with distilled
water five times and mounted onto a slide. Images were captured
using a panoramic digital slide scanner. Non-treated cells were
used as control.
Quantitative Real-Time PCR
Total RNA was extracted from SAT using RNeasy Lipid
Tissue MiniKit (Qiagen, CA, USA). For cell lines, total RNA
was extracted using TRIZOL reagent. cDNA was synthesized
from total RNA samples using High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, CA, USA). Conventional
qRT-PCR was performed using the Applied Biosystem7500
systemwith Taqman gene expression assays normalized to gapdh.
The primers used are presented in Table S1. The differences
in gene expression between groups were assessed using the
11CT method.
Western Blot Analysis
Western blots were performed using 3T3-L1 cells. Whole
cell extracts were prepared in RIPA buffer (50mM Tris-HCl,
pH 7.5, 150mM NaCl, 1% Triton X-100, 1mM EDTA, 0.5%
sodium deoxycholate, and 0.1% SDS). Protein concentration
was determined by the Bradford method using β-globulin as a
standard. Twenty microgram of protein was prepared in sample
loading buffer containing β-mercaptoethanol heated at 95◦C for
10min, then resolved on 12% SDS-PAGE gels. Proteins were
then transferred at 100V for 75min onto PVDF membranes,
blocked with 5% non-fat dried milk in Tris-buffered saline
containing 0.05% Tween 20 (TBST) for 2 h at RT, and then
probed with the anti-UCN3 primary antibody (1:1,000 dilution)
(bs-2786R, Bioss Antibodies Inc., MA, USA) for overnight
at 4◦C. After washing, the membranes were incubated with
Rabbit horseradish peroxidase conjugated secondary antibody
(1:10,000 dilution) for 2 h at RT, and finally detection was
performed using super sensitivity West Femto ECL reagent
(Thermo Scientific, USA). Protein bands were visualized by
chemiluminescence and the images captured by using the
Versadoc 5000 system (Bio-Rad, USA). GAPDH was used as
internal control to monitor for protein loading, with the anti-
GAPDH (ab2302, Millipore, Temecula, CA). For densitometric
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analysis, the intensity of bands was determined using Quantity
One Software (Bio-Rad, USA).
Statistical Analysis
SPSS software (v25.0; SPSS Inc., IL, USA) was used to perform
the statistical analyses. All descriptive statistics in the study
are reported as mean ± standard deviation. A Chi-square
test was used for categorical variables and the Wilcoxon non-
parametric t-test was used for skewed variables. To evaluate
the effects of groups, we conducted two-way repeated measures
ANOVA test with post-hoc Bonferroni on the whole population.
A paired t-test was used to determine the significance of
differences in means within each group before and after
exercise. Correlations between variables were calculated using
the Spearman’s correlation coefficient. Multivariable linear
regression analysis was performed to examine the predictive
effect of each factor with odd ratios (ORs), and their 95%
confidence intervals for associated factors were estimated. All
p< 0.05 were considered statistically significant.
RESULTS
Plasma UCN3 Levels Are Affected by
Obesity and T2D
Table 1 shows the characteristics of the study participants.
Briefly, the overweight with T2D group showed more
dysregulated lipid profile as reflected by lower HDL (p <
0.01) and higher TGL levels (p < 0.001) than the normal weight
and overweight without T2D groups. Moreover, the overweight
without T2D group displayed significantly higher systolic
blood pressure (SBP) and lower maximal oxygen consumption
(VO2max) levels than the normal-weight group (p < 0.01),
whereas the overweight with T2D group had the highest SBP (p
< 0.05) and lowest VO2max (p< 0.01). Altered hormone profiles
were also observed in the overweight groups, with higher levels
of leptin, glucagon, glucagon-like peptide-1 (GLP-1), and gastric
inhibitory polypeptide (GIP) than the normal-weight group
(p < 0.05). The levels of circulating UCN3 were significantly
decreased with increased body mass index (BMI) (p < 0.001)
and significantly increased with T2D in the overweight group (p
< 0.01) (Table 1).
Considering the observed increased UCN3 levels with T2D,
we further assessed UCN3 levels by dividing the T2D group into
controlled and uncontrolled HbA1c groups (HbA1c< 6.5%;<48
mmol/mol and HbA1c ≥ 6.5%; ≥48 mmol/mol, respectively).
UCN3 levels were significantly higher in the uncontrolled HbA1c
group than in the controlled HbA1c group (5.9± 3.6 and 11.7±
8.8 ng/ml, respectively; p< 0.05).
Spearman’s correlation analysis between UCN3 plasma levels
and various parameters was performed for all participants and
separately for each group (Table 2). Briefly, UCN3 levels were
positively correlated with TGL and visfatin/eNAMPT (p < 0.05)
but were negatively correlated with insulin (p < 0.01) in the
whole population and in the two overweight groups separately.
Moreover, UCN3 levels were significantly correlated with FPG
and HbA1c (p < 0.05) but were negatively correlated with
RANTES (p< 0.05) in all subjects.
TABLE 1 | Physical, clinical, and biochemical characteristics of the subjects
at baseline.
Normal-
weight
(n = 37)
Overweight
non-diabetic
(n = 107)
Overweight
diabetic
(n = 98)
Sig.
PHYSICAL AND CLINICAL CHARACTERISTICS
Gender (M/F) 14/23 42/65 53/45 0.379
Age (years) 40 ± 11 42 ± 12 52 ± 9$$$ < 0.0001
BMI (kg/m2) 22.3 ± 1.9 31.9 ± 4.5*** 32.3 ± 3.7 < 0.0001
PBF (%) 29.5 ± 5.7 36.6 ± 5.9*** 36.1 ± 5.4 < 0.0001
Waist (cm) 77.1 ± 9.6 99.7 ± 12.2*** 105.7 ± 10.56$$ < 0.0001
Hip (cm) 98.0 ± 5.6 113.7 ± 11.9*** 111.4 ± 11.6 < 0.0001
Resting HR
(beats/min)
80.9 ± 7.6 78.4 ± 10.4 82.3 ± 13.2 0.090
SBP (mmHg) 106.4 ± 10.1 115.6 ± 10.6** 119.1 ± 11.7$ < 0.0001
DBP (mmHg) 71.4 ± 6.6 74.3 ± 7.3 75.6 ± 6.3 0.091
WBC10 6.2 ± 1.6 6.4 ± 1.6 7.5 ± 2.0$$$ < 0.0001
VO2, max
(ml/kg/min)
23.0 ± 5.1 18.0 ± 3.8*** 15.7 ± 4.2$$ < 0.0001
METABOLIC MARKERS
Cholesterol
(mmol/l)
5.06 ± 1.07 5.10 ± 0.91 4.84 ± 1.33 0.248
HDL (mmol/l) 1.46 ± 0.43 1.31 ± 0.38 1.14 ± 0.37$$ 0.0003
LDL (mmol/l) 3.11 ± 0.88 3.27 ± 0.85 2.97 ± 1.17 0.102
TGL (mmol/l) 0.89 ± 0.78 1.15 ± 0.63 1.64 ± 1.16$$$ < 0.0001
FPG (mmol/l) 5.12 ± 0.66 5.34 ± 0.85 8.37 ± 3.12$$$ < 0.0001
HbA1c (%)
(mmol/l)
5.5 ± 0.4 5.7 ± 0.9 7.8 ± 1.8$$$ < 0.0001
Insulin (ng/ml) 2.74 ± 1.15 3.68 ± 2.19* 3.98 ± 1.95 0.012
(37) (39) (62)
C-peptide (ng/ml) 3.35 ± 4.43 5.77 ± 6.77 4.10 ± 5.50 0.073
HOMA-IR 0.60 ± 0.24 0.89 ± 0.37* −− < 0.0001
HORMONAL MARKERS
Ghrelin (pg/ml) 920 ± 636 564 ± 225*** 550 ± 232 < 0.0001
GIP (pg/ml) 431 ± 267 770 ± 684* 888 ± 585 0.005
GLP-1 (pg/ml) 255 ± 45 272 ± 50 295 ± 64$ 0.004
Glucagon (pg/ml) 145 ± 46 159 ± 45 179 ± 55$ 0.006
Leptin (ng/ml) 4.4 ± 2.6 9.2 ± 5.6*** 7.9 ± 4.6 < 0.0001
Resistin (ng/ml) 3.0 ± 0.8 3.5 ± 1.7 3.3 ± 1.1 0.282
Visfatin (ng/ml) 3.6 ± 1.5 4.1 ± 3.1 4.5 ± 2.3 0.361
INFLAMMATORY MARKERS
IL-1b (pg/ml) 10.2 ± 6.0 8.5 ± 3.0 8.5 ± 2.2 0.0560
IL-6 (pg/ml) 17.3 ± 4.8 17.1 ± 5.8 18.9 ± 8.7 0.2931
TNF-a (pg/ml) 138 ± 32 128 ± 38 140 ± 81 0.4590
RANTES (ng/ml) 7.5 ± 1.3 7.9 ± 1.6 8.2 ± 1.4 0.159
PAI-1 (ng/ml) 13.1 ± 5.2 15.2 ± 4.9 17.0 ± 6.4 0.007
hsCRP (µg/ml) 2.1 ± 1.2 5.2 ± 3.3 5.6 ± 4.7 0.174
OTHER MARKERS
UCN3 (ng/ml) 11.99
(0.78–86.07)
6.27
(0.64–77.04)***
9.03
(0.77–104.92)$$
0.00015
Data are presented as the mean ± SD. HR, heart rate; SBP, systolic blood pressure;
DBP, diastolic blood pressure; VO2, max, maximum oxygen consumption; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; TGL, triglyceride; HbA1c, hemoglobin
A1c; hsCRP, high-sensitivity CRP. Sig (significant) of 2-way ANOVA. *p< 0.05, **p< 0.01,
***p < 0.001 where * is significance between normal weight and overweight non-diabetic.
$p < 0.05, $$p < 0.01, $$$p < 0.001, where $ is significance between overweight
non-diabetic and diabetic.
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TABLE 2 | Spearman Correlation ranking of UCN3 with subject characteristics
at baseline.
All All
non-diabetic
Normal-
weight
Overweight
non-diabetic
Overweight
diabetic
Age (years) 0.07 −0.01 −0.25 0.09 0.11
BMI (kg/m2 ) −0.02 −0.21* −0.13 0.09 0.17
PBF (%) −0.11 −0.17 −0.08 −0.16 −0.02
Waist (cm) 0.13 −0.03 0.01 0.04 0.12
Hip (cm) −0.10 −0.10 −0.09 −0.04 −0.15
HR
(beats/min)
−0.05 −0.10 0.27 −0.15 −0.06
SBP (mmHg) 0.17* 0.08 0.47 0.08 0.21*
DBP (mmHg) 0.11 0.04 0.30 0.04 0.13
VO2max
(ml/kg/min)
0.04 0.08 −0.09 0.06 0.21
Cholesterol
(mmol/l)
0.09 0.09 −0.03 0.13 0.14
HDL (mmol/l) −0.09 −0.04 0.04 −0.11 −0.01
LDL (mmol/l) 0.07 0.12 0.05 0.19 0.03
TGL (mmol/l) 0.21** 0.13 −0.11 0.24* 0.23*
FPG (mmol/l) 0.16* 0.05 −0.10 0.12 0.09
HbA1c (%) 0.20** 0.12 −0.08 0.21* 0.11
Insulin (ng/ml) −0.22** −0.28** −0.18 −0.25** −0.22*
C-peptide
(ng/ml)
−0.07 −0.19* −0.04 −0.14 0.17
HOMA1 −0.12 −0.23* −0.17 −0.20 −0.16
IL-1b (pg/ml) 0.09 0.12 0.07 0.09 0.04
IL-6 (pg/ml) 0.12 0.04 0.03 0.09 0.11
TNF-a (pg/ml) 0.03 0.01 0.12 −0.11 0.08
RANTES
(ng/ml)
−0.17* −0.13 −0.39* −0.02 −0.30*
hsCRP
(µg/ml)
−0.10 −0.07 −0.30 −0.06 −0.15
Ghrelin
(pg/ml)
0.13 0.11 −0.33 0.08 0.21
GIP (pg/ml) −0.04 −0.12 −0.03 0.02 0.04
GLP-1 (pg/ml) 0.23** 0.17 0.19 0.27* 0.26*
Glucagon
(pg/ml)
0.16* 0.14 0.35 0.19 0.16
Leptin (ng/ml) −0.18* −0.18 −0.11 −0.02 −0.21
PAI-1 (ng/ml) −0.04 −0.09 0.11 −0.07 −0.04
Resistin
(ng/ml)
−0.06 0.02 −0.15 0.12 −0.22
Visfatin
(ng/ml)
0.36** 0.32** 0.26 0.37** 0.40**
Data are presented as the R-values. HR, heart rate; SBP, systolic blood pressure; DBP,
diastolic blood pressure; VO2max , maximum oxygen consumption; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; TGL, triglyceride; HbA1c, hemoglobin A1c;
hsCRP, high-sensitivity CRP. Significance of spearman correlation are as follows *p <
0.05, **p < 0.01.
To further assess the independent association of UCN3 with
these markers, a multivariate stepwise linear regression analysis
for UCN3 as a dependent variable was performed separately
for the whole study population and separately for each group
(Table 3 and Table S2). Independent associations were observed
between UCN3 levels and FPG, HbA1c, GLP-1, and RANTES
TABLE 3 | Multivariate Linear Regression analysis with UCN3 as
dependent variable.
Independent
variables
All subjects Overweight
non-diabetic
Overweight
diabetic
β
coefficient
p value β
coefficient
p value β
coefficient
p value
Age 0.120 0.200 0.190 0.212 −0.071 0.606
Gender −0.017 0.874 −0.294 0.067 −0.040 0.813
TGL 0.010 0.913 −0.015 0.909 0.045 0.721
FPG −0.293 0.019* −0.194 0.204 −0.380 0.042*
HbA1c 0.413 0.001* 0.501 0.001* 0.332 0.040*
Insulin −0.125 0.166 −0.100 0.458 −0.268 0.078
GLP-1 0.310 0.010* 0.186 0.264 0.375 0.033*
Glucagon −0.179 0.111 −0.009 0.949 −0.381 0.068
Leptin −0.117 0.265 0.221 0.179 −0.238 0.170
Visfatin 0.091 0.325 0.242 0.078 0.198 0.174
RANTES −0.298 0.001* −0.162 0.200 −0.455 0.001*
*p < 0.05 significant.
in the whole study population and in the overweight with T2D
group (p< 0.05; Table 3). In the overweight without T2D group,
only HbA1c was independently associated with circulating UCN3
levels (p < 0.05). Multivariate binary logistic regression analyses
were then performed using either normal-weight or overweight
without T2D as reference (Table 4 and Table S3). Plasma UCN3
levels were strongly related to adiposity for both overweight
groups with and without T2D when compared to normal-weight
(OR = 2.11 [1.84–4.11, 95% CI] and OR = 2.12 [1.59–3.10, 95%
CI], p< 0.01, respectively).
A pairwise comparison of UCN3 levels was also performed
using various clinical and metabolic parameters in a subset of
overweight subjects (BMI ≥ 30 kg/m2, n = 39 for each group)
before and after exercise to assess the effect of 3 months of
moderate physical exercise. We previously reported the impact
of exercise on various markers and showed that it was more
prominent in people without T2D, where adiposity markers
[BMI, waist circumference, and percent body fat (PBF)] were
significantly decreased, along with ameliorated cardiorespiratory
markers (HR and VO2max) (25, 28). Table S4 summarizes
the markers significantly affected by exercise in our cohort.
Despite an increase in UCN3 plasma levels with exercise in
the overweight without T2D and overweight with T2D groups,
statistical significance (p < 0.05) was reached only in the
overweight without T2D group.
UCN3 Expression Is Increased in SAT From
Overweight Individuals and Decreased by
Physical Exercise and Inflammation
To elucidate the role of UCN3 in obesity and T2D, we
assessed UCN3 expression levels in SAT from representative
individuals from the three groups. Our results revealed an
opposite pattern of UCN3 expression in SAT from those seen
in blood (Figures 1A,B). UCN3 expression was significantly
increased at both the protein (p < 0.01) (as observed by
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TABLE 4 | Odds Ratio analysis by binary logistic regression models compared to normal-weight subjects.
Covariates Normal weight Overweight non-diabetic Overweight diabetic All overweight
Reference OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
UCN3 1.00 2.11 (1.84–4.11) 0.009* 2.12 (1.59–3.10) 0.008* 2.80 (1.94–4.13) 0.017*
TGL 1.00 1.86 (0.61–5.67) 0.278 0.83 (0.35–1.97) 0.677 2.86 (1.61–5.63) 0.037*
RANTES 1.00 1.00 (1.00–1.01) 0.937 1.00 (1.00–1.00) 0.068 1.00 (1.00–1.00) 0.486
C-Peptide 1.00 1.01 (1.00–1.02) 0.061 1.00 (0.99–1.00) 0.688 1.00 (1.00–1.02) 0.071
GLP1 1.00 1.01 (0.98–1.03) 0.441 1.03 (0.99–1.07) 0.058 0.99 (0.99–1.03) 0.174
Visfatin 1.00 1.00 (1.00–1.01) 0.219 1.00 (0.99–1.00) 0.437 1.00 (1.00–1.01) 0.384
Model adjusted for age and gender, *p < 0.05 significant.
FIGURE 1 | UCN3 expression levels in subcutaneous adipose tissue (SAT). (A) Representative confocal immunofluorescence images illustrating UCN3 expression
and localization in SAT from normal-weight, overweight people with and without T2D (n = 10 for each group). Staining quantification of SAT was performed as detailed
in Materials and Methods and data are presented as arbitrary unit. (B) mRNA expression of Ucn3 in the subcutaneous adipose tissue (SAT) of participant groups.
mRNA levels were measured by quantitative real-time PCR using SAT from normal-weight and overweight people with and without T2D and PCR products were run
on agarose gel. GAPDH was used as an internal control for normalization and data are presented as fold changes compared with the findings in the normal-weight
participant. (C) Representative confocal immunofluorescence images illustrating UCN3 expression and localization in SAT from overweight individuals with and without
T2D before and after 3-month physical exercise (n = 6 for each group). Staining quantification of SAT was performed as detailed in Materials and Methods and data
are presented as arbitrary unit. The p-value was determined using the Wilcoxon test was used for comparisons between each 2 groups separately and a paired t-test
for intragroup comparisons before and after exercise. *p < 0.05, **p < 0.01, ***p < 0.001.
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confocal IF staining) and mRNA (p < 0.001) levels in the
overweight without T2D individuals compared with the normal-
weight individuals. However, UCN3 expression was significantly
decreased in the overweight with T2D individuals compared
with those without T2D (p < 0.05 and p < 0.001 for protein
and mRNA, respectively). As a control, adiponectin staining
was assessed in SAT from the same individuals and revealed
lower levels in the overweight without T2D individual compared
with the normal-weight individual and was further decreased
in the overweight with T2D individual (Figure S1). We also
examined the effect of a 3-month moderate physical exercise
program on UCN3 expression levels in SAT from overweight
individuals. SAT UCN3 expression levels were significantly
reduced after exercise in both overweight groups regardless of
the presence or absence of T2D (p < 0.01), as indicated by the
clear decrease in UCN3 protein staining assessed by IF confocal
microscopy (Figure 1C).
We previously reported the differential patterns of stress
and inflammation markers in the SAT of normal-weight
and obese individuals, as well as between individuals with
and without T2D (25, 28). This, along with the correlation
of UCN3 with RANTES in our current study, prompted
us to assess the effect of inflammation on its expression
levels during preadipocyte differentiation with and without
macrophage conditioned media (MaCM). By using the murine
3T3-L1 cells, we showed that both UCN3 mRNA and
protein were expressed in both the preadipocyte (day 0) and
adipocyte (day 8) phenotypes (Figures 2A,B). Furthermore,
adipogenic stimuli–induced differentiation markedly increased
both UCN3 mRNA and protein levels in mature adipocytes
FIGURE 2 | Expression levels of Ucn3 before and after differentiation of 3T3 preadipocytes. Protein (A) and mRNA (B,C) levels were measured by Western blot and
quantitative real-time PCR, respectively, using 3T3-L1 preadipocytes (D0), adipocytes differentiated for 8 days (D8) with and without macrophage conditioned media
(MaCM). Data are presented as fold changes in differentiated adipocytes compared with the findings in preadipocytes from 3 independent experiments. (D)
Representative images for Oil Red O staining illustrating differentiation under normal and MaCM conditions. Images were taken at magnification of 40X. *p < 0.05 and
**p < 0.01.
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(day 8, p < 0.05) (Figures 2A,B) as well as UCN3 receptor
(CRHR2) (Figure 2C). Finally, the differentiation of 3T3-L1
preadipocytes in the presence of MaCM strongly reduced
UCN3 levels in differentiated adipocytes at both mRNA
and protein levels (p < 0.05) and its receptor, as well
as lipid droplet accumulation (Figures 2C,D). The increased
levels of expression of genes related to lipogenesis (FASBP4,
FASN), lipolysis (LPL, LIPE), inflammation (IL6) as well
as C/EBP and PPARG indicated that cell differentiation
is achieved both in the presence and absence of MaCM
(Figure 2C).
DISCUSSION
This study is the first to report UCN3 levels in blood and SAT
from normal and overweight adults with and without T2D and
the modulation of UCN3 levels by physical exercise. The main
findings of this study are: (1) plasma UCN3 levels decreased with
BMI; (2) UCN3 plasma levels were independently associated with
glycemic index (FPG, HbA1c) and were significantly different
between overweight individuals with and without T2D; (3) the
UCN3 expression in SAT was increased with BMI and blunted
with T2D; and (4) a 3-month supervised exercise protocol
showed a significant reduction of UCN3 expression in both
overweight group SAT.
Our findings of impaired UCN3 levels in obesity and T2D
with opposite pattern between plasma and SAT indicate the
complexity of mechanisms under these conditions. Despite the
well-established role of impaired feedback in the inhibition of
insulin secretion in hyperinsulinemia and insulin resistance (29,
30), multiple central and peripheral endocrine and inflammatory
pathways are also disturbed. UCN3 was reported to be co-
released with insulin from β-cells and acts in a paracrine fashion
on delta cells to trigger the release of somatostatin and limit
further insulin release (12). However, the role of UCN3 in obesity
and diabetes is not well-understood. To date, most studies into
urocortins have focused on UCN1 and UCN2 in various diseases
including heart failure (HF) and have revealed compelling data
on the endogenous compensatory role of UCN1 and UCN2
and their cardioprotective effects (31, 32). During gestation, the
placenta does not secrete significant UCN2 and UCN3 into the
plasma despite the increased plasma CRF levels (33). Placental
UCN2 and UCN3 levels likely function as autocrine/paracrine
messengers during pregnancy. Interestingly, initial studies have
suggested that a negative relationship exists between UCNs
concentration and their pharmacokinetics (34). Furthermore,
UCN3 is present in urine, and levels are significantly increased in
patients with obstructive sleep apnea (35). These findings reflect
variations inUCNpatterns, particularly UCN3, depending on the
tissue and disease.
In line with this and contrary to the pattern of circulating
UCN3 observed in our study population, we found that UCN3
expression SAT increased with obesity and blunted with T2D
in this tissue likewise previous reports showing decreased levels
of UCN3 in β-cells people with diabetes (12). In plasma,
our data demonstrate an association between UCN3 levels
and glycemic index in individuals with and without T2D,
thus further supporting the involvement of UCN3 in glucose
homeostasis and/or insulin regulation. Within the overweight
group, the significantly high OR (2.24) of circulating UCN3
in individuals with T2D compared with those without T2D
supports the involvement of UCN3 in diabetes (Table S3). The
strong correlation observed between UCN3, TGL, and visfatin
in plasma further indicates global metabolic disturbance due to
obesity and hyperglycemia in our study population. However, the
role and involvement of circulating UCN3 in diabetes are yet to
be elucidated.
Although UCN3 is expressed in human adipocytes and
adipose tissue (36, 37), its role in obesity and diabetes has not
been reported. Giamouridis et al. (38) demonstrated that UCN3
gene transfer showed promising potential as a treatment for
HF and had significant beneficial effects on glucose control,
weight loss, and liver fat reduction. UCN3 was also reported
to circulate in normal human plasma, and its possible sources
included a range of tissues such as heart, brain, kidney, stomach,
intestine, pancreas, muscle, and vasculature, thus suggesting
that UCN3 has a hormonal role (3, 39). However, the source,
concentrations, and forms of UCN3 in plasma remain to be
determined. Similarly, the contribution and amount of UCN3
secreted from adipose tissue into the circulation remain to be
elucidated, and it is possible that adipose tissue UCN3 plays a
paracrine/autocrine hormonal role. Nevertheless, the opposite
pattern of UCN3 observed in the SAT and plasma in the present
study does not support a significant contribution or secretion
from SAT to circulating levels of UCN3. Our findings do not rule
out the possibility that UCN3may be released from adipose tissue
to a greater extent into the plasma under other conditions and
diseases, in particular from visceral adipose tissue where UCN3
might be more abundant (32). Nevertheless, we can exclude the
significant uptake of UCN3 by SAT owing to diabetes because of
the observation of opposite UCN3 profiles in plasma and SAT
and the fact that UCN3 mRNA levels paralleled those of protein
levels in SAT.
On the other hand, the observation that the expression
of UCN3 mRNA and protein in SAT was increased by the
adiposity but not by the concomitant presence of T2D in
overweight subjects might indicates that, UCN3 expression
is primarily associated with SAT expansion. In addition, in
diabetic obese SAT, we and others have previously reported
further increased inflammation and ER stress (24, 40). This
suggests that an altered local microenvironment may affect
UCN3 expression in obese diabetic adipose tissue. Indeed,
our experiments using conditioned media from macrophages
to culture 3T3-L1 adipocytes markedly repressed UCN3 gene
expression (Figure 2). Moreover, association between RANTES
as inflammatory mediator and UCN3 was found in the obese
subjects with diabetes but not without diabetes (Table 2). Thus, it
appears that UCN3 up-regulation in human SAT is closely related
to the metabolic derangements associated with greater adiposity
(hypertrophy). UCN3 might participates in local adaptive
inflammation and stress for maintaining tissue homeostasis but
this effect might be blunted with excessive and chronic cellular
stress, as in diabetes, and reflected by decreased levels of UCN3 in
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the SAT. Similar pattern have been observed in our previous work
on the heat shock protein 60 (HSP60) were attenuated in normal-
weight subjects with diabetes, in comparison with non-diabetic
controls, along with increased expression of the inflammatory
markers IL-6 and TNF-α, as observed in our overweight subjects
(25).This suggests an autocrine/paracrine role of UCN3 in SAT
which is further supported by the opposite trend observed in
plasma. Interestingly, The Odd Ratios (OR) analysis for plasma
UCN3 showed that UCN3 levels are more affected by the obesity
than diabetes (see Table 4).
Furthermore, SAT expansion in obesity is known to create
hypoxic microenvironment which amplifies inflammation and
hyperglycemia (41). Interestingly and more recently, it was
shown that in WAT hypoxia, lipolysis was significantly increased
by activating Ucn2/3–CRHR2–cAMP–PKA pathway in an
autocrine/paracrine manner (42). In line with this, transgenic
UCN3+ mice exhibited a favorable metabolic phenotype
resisting obesity and hyperglycemia with improved fatty acid
metabolism. This supports that UCN3 plays a role in maintaining
energy and glucose homeostasis in adipose tissue (9). Finally,
stem cells differentiation in the SAT of diabetic individuals
is impaired (43). T2D and aging are also associated with
increased SAT stem cell senescence, reduced adipogenesis and
hypertrophic expansion (44). It is worth to mention here, that
our diabetic subjects are more aged than the non-diabetic ones.
Altogether, those processes might explain the impaired UCN3
expression in diabetic compared to non-diabetic subjects.
Physical exercise reduces the risk of chronicmetabolic diseases
by modulating inflammatory and stress responses. Our data
showed that a 3-month supervised exercise program significantly
increased circulating UCN3 levels in the overweight without
T2D group concomitant with the decreased PBF and waist
circumference and improved VO2max. The increase in UCN3
levels was also consistent with reduced insulin levels. We and
others have previously reported the beneficial effects of regular
exercise in individuals without T2D compared with those with
T2D (25, 28, 45). Our findings demonstrate that the exercise-
mediated increase in circulating UCN3 was not translated
to an increase in SAT UCN3. On the contrary, SAT UCN3
levels were decreased in both the overweight groups. A lack
of parallel changes between SAT and circulating UCN3 levels
raises questions about the role of UCN3 from different tissue
sources and its mode of action but partly supports the suggested
autocrine/paracrine role of UCN3 in SAT. Interestingly, the
SAT UCN3 expression pattern between the three groups was
similar to the one observed in PBMCs (data not shown). The
difference in the patterns of circulating and SAT UCN3 indicates
that dysregulation is not limited to SAT; therefore, it would be
of interest to investigate its status in other UCN3-producing
tissues. Data on the effect of exercise on UCN3 in health
and diseases are limited. However, previous studies suggested
a link between exercise and the central responsiveness of the
hypothalamic-pituitary-adrenal axis, including the activation of
the CRF system and increased corticosterone level secretion
(46, 47).
Despite our novel findings, this study has some limitations.
First, we did not have access to visceral adipose tissue biopsies,
which would be more relevant to the pathophysiology of diabetes
and obesity. Second, urine samples were not collected to assess
UCN3 clearance in the various phenotypes. Third, despite our
adjustment for many confounders, we cannot exclude that some
of the associations we have observed can be due to other variables
including; the lack of detailed medication of our subjects and
controlled dietary intake which may have affected UCN3 levels
and efficacy of physical exercise despite the marginal observed
body-weight loss. Furthermore, diabetes is associated with aging,
and it was difficult to find age-matched healthy obese controls.
Finally, we did not consider the potential contribution of UCN3
gene polymorphism in our data analysis as we did not have
to this information. UCN3 gene polymorphisms have been
reported to contribute to adiposity and intramuscular adipose
deposition (18). However, the strengths of this study include
that it involved high-risk group of obese adults with or without
T2D who underwent a supervised moderate exercise protocol
as a behavioral approach to improve global health without diet
restriction. However, further studies are required to understand
the cross talk between UCN3 levels and insulin resistance, and
its role in adipose tissue, including the status of CRF receptors
in SAT. These studies will help elucidate the mechanisms
involved in the differential patterns seen between circulating and
endogenous UCN3 levels.
CONCLUSIONS
We found that UCN3 is associated with markers of glucose
metabolism in humans and that there is differential dysregulation
of UCN3 levels with obesity and T2D in plasma and SAT. Our
results also show that moderate physical exercise differentially
modulates UCN3 levels in the body and provides further
evidence for the effect of physical exercise inmitigatingmetabolic
stress linked with obesity and insulin resistance.
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